No abstract available
MeSH terms
-
Antiviral Agents / adverse effects*
-
Antiviral Agents / therapeutic use
-
Cyclosporine / blood
-
Cyclosporine / pharmacokinetics
-
Cyclosporine / therapeutic use
-
Cytochrome P-450 Enzyme Inhibitors*
-
Dose-Response Relationship, Drug
-
Drug Interactions
-
Hepatitis C / drug therapy
-
Hepatitis C / prevention & control
-
Humans
-
Immunosuppressive Agents / blood
-
Immunosuppressive Agents / pharmacokinetics*
-
Immunosuppressive Agents / therapeutic use
-
Liver Transplantation / immunology
-
Oligopeptides / adverse effects*
-
Oligopeptides / therapeutic use
-
Proline / adverse effects
-
Proline / analogs & derivatives*
-
Proline / therapeutic use
-
Tacrolimus / blood
-
Tacrolimus / pharmacokinetics
-
Tacrolimus / therapeutic use
Substances
-
Antiviral Agents
-
Cytochrome P-450 Enzyme Inhibitors
-
Immunosuppressive Agents
-
Oligopeptides
-
telaprevir
-
Cyclosporine
-
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
-
Proline
-
Tacrolimus